{"id":"W4296962943","doi":"10.1016/s2152-2650(22)00747-9","title":"Poster: AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; McGill University; University of Toronto; Jewish General Hospital","funders":"","keywords":"Venetoclax; Azacitidine; Myeloid leukemia; Medicine; Internal medicine; Myeloid; Oncology; Leukemia; Biology; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":{"n_in":0,"stratum":"aff_core","weight":5595.2375,"opus":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"Conference poster reporting first results of a phase II AML treatment study; a clinical trial report."},"gpt":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"It reports a leukemia treatment study rather than studying research practice."},"grok":{"tier":"OUT","genre":"other","about_ca":false,"confidence":"high","reason":"AML clinical trial poster of a drug study; domain oncology trial, not research-on-research."}},"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009439947,0.0007954055,0.001086509,0.0002336697,0.0004538032,0.0006577686,0.0005634226,0.001060751,0.01873073],"category_scores_gemma":[0.0009426075,0.0002366012,0.001073631,0.0001062675,0.000366194,0.0003125926,0.0002927126,0.001998365,0.001980489],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00052711,"about_ca_system_score_gemma":0.000732376,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009002176,"about_ca_topic_score_gemma":0.00159573,"domain_scores_codex":[0.9997144,0.0001288061,0.00002007974,0.00004306304,0.00002558559,0.00006808642],"domain_scores_gemma":[0.999408,0.0001800369,0.00005571913,0.00002982837,0.00003772713,0.0002885719],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6437696,0.01834082,0.007040547,0.001438804,0.001592347,0.0007470133,0.0001852435,0.001879749,0.04271353,0.0005275067,0.06180193,0.2199628],"study_design_scores_gemma":[0.5424903,0.3228989,0.04639548,0.0001907694,0.002359384,0.0009932194,0.00008564344,0.001409814,0.02557107,0.0006348553,0.05691363,0.00005690407],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9346437,0.01407554,0.001265506,0.01162292,0.004217195,0.003574959,0.009570746,0.0004722317,0.02055719],"genre_scores_gemma":[0.9238199,0.005981079,0.002728123,0.008679464,0.004043912,0.001876489,0.009057139,0.0001340403,0.04367997],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01873073,"threshold_uncertainty_score":0,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02836306749547465,"score_gpt":0.3261240952854576,"score_spread":0.2977610277899829,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}